摘要
《中国成人血脂异常防治指南》(以下简称《指南》)在吸收国内外循证医学证据和经验的基础上,结合我国人群的特点来制定的,尤其是在血脂异常分层切点的确定上,参照我国的流行病学资料,更符合国人的情况。在危险分层上本《指南》将高血压单列,等同于任何其他3项危险因素的集合,对极高危人群的确定更明确,目标值也符合临床实际,更加强调了血脂异常的非药物治疗,以及药物治疗中他汀类药物的地位,并且要关注调脂治疗中的监测。
“China adult dyslipidemia Prevention Guide” is formulated by combining the characteristics of Chinese population,on the basis of domestic and international evidencebased medicine evidence and experience, Especially in the determination of the stratification cut point of dyslipidemia, it is more consistent with the Chinese situation,confering with Chinese epidemiological data.In the risk stratification,the “Guide” separates the factor of hypertension,being equivalent to the other three risk factors.Decision of the very high risk crowd is more clearer, and the goal value is also consistent with clinical practice.The “Guide” emphasizes on the non-drug therapy to dyslipidemia,and the position of the statins drug in drug therapy, and pays attention to the monitoring of lipid accommodation.
出处
《医学与哲学（B）》
2008年第2期22-26,45,共6页
Medicine & Philosophy(B)
关键词
血脂异常
指南
目标值
他汀类
dyslipidemia,Guide,stratification,statins
作者简介
李晓东，男，心内科副主任，教授，硕士生导师，研究方向：高血压及相关疾病基础和临床研究，动脉粥样硬化发生机制。
